Paper Details

  1. Home
  2. Paper Details

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Author:

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This article discusses the potential role of interferon beta in treating patients with secondary progressive multiple sclerosis (SP-MS).
Paper Details　
Original Abstract of the Article :
The beneficial effects of interferon beta have only been shown for patients in the relapsing-remitting phase of multiple sclerosis (MS). The role of interferon beta in the treatment of patients who are in the secondary progressive phase of the disease (SP-MS), and for whom no effective drug treatmen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9820296

データ提供：米国国立医学図書館（NLM）

Interferon Beta-1b: A Search for Relief in Secondary Progressive Multiple Sclerosis

Multiple sclerosis (MS), a chronic and debilitating autoimmune disease, affects the central nervous system. This study explores the potential of interferon beta-1b, a medication used to treat relapsing-remitting MS, in managing secondary progressive MS (SP-MS). The researchers conducted a placebo-controlled, multicenter, randomized trial to assess the effectiveness of interferon beta-1b in patients with SP-MS, a form of the disease characterized by gradual neurological decline.

Navigating the Complexities of MS Treatment

The study, like a journey across a vast and shifting desert landscape, reflects the complex challenges of treating MS. The findings provide valuable insights into the potential benefits and limitations of interferon beta-1b in SP-MS, highlighting the need for further research and tailored treatment approaches for this complex condition.

A Continued Search for Effective Treatments

This research underscores the ongoing need for effective treatments for SP-MS. The findings highlight the complexity of this disease and the ongoing search for therapies that can slow or halt its progression.

Dr. Camel's Conclusion

This study, like a quest for a hidden oasis in the desert of MS research, explores the potential of interferon beta-1b in managing SP-MS. The findings provide valuable insights into the complexities of this disease while highlighting the need for continued research and development of new and effective treatments.

Date :
  1. Date Completed 1998-12-04
  2. Date Revised 2015-06-16
Further Info :

Pubmed ID

9820296

DOI: Digital Object Identifier

S0140673698100399

Related Literature

Article Analysis
・Side Effects of interferon beta-1b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.